InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,841.47
(
-0.02%
)
US TECH 100
19,726.80
(
0.39%
)
Dow Jones
43,239.05
(
0.37%
)
Brent Oil
73.85
(
-0.42%
)
Bitcoin
67,793.35
(
0.55%
)
Post# of 253393
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dewophile

Send PM Follow Ignore
Followers 47
Posts 4724
Boards Moderated 0
Alias Born 07/19/2006

dewophile

Re: DewDiligence post# 228220

Tuesday, 01/14/2020 8:01:43 AM

Tuesday, January 14, 2020 8:01:43 AM

Post# of 253393

Based on this new info, EDP-297 would seem to be a better horse to back than EDP-305



I think it makes sense to continue development of both since 305 is so far ahead. ENTA wants to partner in NASH so they presumably would include both compounds in a deal and with 305 have the potential to have a drug not too far behind others in combinations in NASH for a first wave if you will for a larger pharma to get a foothold in the space and then hopefully get a better safety or efficacy with the follow on compound
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up